Fyarro
Biological Oncology
NDC 80803-153-50
General payments
$52,175
Research payments
$15,911,882
Through program year 2025, $52,175 in general payments and $15,911,882 in research payments were reported against Fyarro (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $52,175 | 6 |
| 2025 | Research | $425,021 | 7 |
| 2024 | Research | $15,486,862 | 47 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
6 general · 54 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.